drugset

drugset / Trial / NCT01318837

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment

NCT01318837 ↗

Phase 4 Completed 100 enrolled Astellas Pharma Inc Astellas Pharma Korea, Inc. · collab

Non-randomizedParallel-groupOpen-label

Summary

This study is to evaluate change of over active bladder symptom scores (OABSS) between, before and after solifenacin treatment to OAB subjects.

Timeline

Start: 2010-04
Primary completion: 2011-09
Completion: 2011-09

Publications

Background Jeong SJ, Homma Y, Oh SJ. Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms. Qual Life Res. 2014 Feb;23(1):285-92. doi: 10.1007/s11136-013-0440-7. Epub 2013 May 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Solifenacin	Small molecule	—	Oral

Indications